Oncolytic Virus-Based Immunotherapy: Mechanistic Insights, Synergistic Design and Translational Frontiers
Oncolytic viruses (OVs) can selectively lyse tumor cells and remodel the immunosuppressive tumor microenvironment. However, monotherapy is limited by low response rates, systemic delivery barriers and antiviral-mediated viral clearance. Combinatorial strategies with immune-checkpoint inhibitors, CAR-T cells, cancer vac...